Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866190 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of SQ109 in Healthy Adult Volunteers
A Phase 1 study of TB Multi-drug Resistant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00866190: Completed Phase 1 study of TB Multi-drug Resistant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00866190 is a Phase 1 study of TB Multi-drug Resistant that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00866190, a Phase 1 study of TB Multi-drug Resistant, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to determine: how safe it is to take SQ109 (an experimental tuberculosis treatment) once a day by mouth for up to 2 weeks in 2 different dosages; how well the body accepts it; how SQ109 enters and leaves the body and blood tissues over time; the amounts that can be detected in the blood; and how long it stays in the body. The study involves 30 volunteers: 24 will receive SQ109 and 6 will receive placebo (inactive substance). Qualified participants will be admitted to the study unit within 28 days from the screening and stay as inpatient for approximately 2 weeks. During this period they will receive study drug and complete all scheduled procedures including multiple blood draws. After discharge, there is a 14 day follow up period. Total study participation is about 56 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SQ109
Study Locations (1)
Kansas
- Quintiles Phase I Services - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00866190 record still lists
NCT00866190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with TB Multi-drug Resistant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00866190 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT00866190 about?
NCT00866190 is a clinical study titled "Dose Escalation Study of SQ109 in Healthy Adult Volunteers". The purposes of this study are to determine: how safe it is to take SQ109 (an experimental tuberculosis treatment) once a day by mouth for up to 2 weeks in 2 different dosages; how well the body accepts it; how SQ109 enters and leaves the body and blood tissues over time; the amounts that can be det...
What is the current status of trial NCT00866190?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-04. Estimated completion is 2009-11.
What conditions does trial NCT00866190 study?
This clinical trial studies the following conditions: TB Multi-drug Resistant.
What interventions are being tested in trial NCT00866190?
The interventions under investigation include: Placebo (DRUG), SQ109 (DRUG).
Who is sponsoring clinical trial NCT00866190?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00866190 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00866190's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia